Dowpharma: dedicated to enabling your success
Dowpharma is exclusively dedicated and resourced to serve the pharmaceutical and biopharmaceutical industries with innovative technology, products, and services to clients in drug discovery, development, manufacturing, and delivery.
• Joint research and development on behalf of our clients
• Analytical support
• Host and expression system selection for biologics
• Route selection and optimization
• Process development from lab scale-up through commercial production
• cGMP manufacturing facilities exclusively reserved for
customer projects
• Integrated raw material access
• Global purchasing power
• Regulatory compliance, including FDA
• Integrated supply chain management
• Environmental stewardship
• Industrial hygiene
• Waste management and disposal
The foundation for our organization is the pharmaceutical; and fine and specialty chemical development and manufacturing capabilities the company retained after divesting Marion Merrell Dow in the mid '90s. This legacy includes a 20+ year history of pristine cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates.
Dowpharma has grown, both internally and externally, through strategic acquisitions and alliances. During the past several years, Dow has acquired:
• Hampshire Chemical Company (HCN chemistry)
• ANGUS Chemical (nitroparaffin chemistry)
• Collaborative BioAlliance (development and manufacturing services in biopharmaceuticals)
• Ascot plc, including Chirotech Technology Limited (world leader in complex chiral synthesis) and Mitchell Cotts Chemicals
The Ascot acquisition added a strong European talent, asset, and technology base, with special strengths in chiral chemistry.
Key alliances include those with Diversa (specialty enzymes for biocatalysis) and Alchemia (carbohydrate synthesis) to further strengthen our ability to provide you the broadest range of solutions.
The result is one of the broadest and deepest resources in the industry. Dowpharma is now one of the largest suppliers of small molecule APIs and offers, perhaps, the broadest technology and asset toolbox for companies looking to outsource development and manufacturing of new drug substances.